Affordable Access

Human Tumor–Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing

Authors
  • tuomainen, katja
  • al-samadi, ahmed
  • potdar, swapnil
  • turunen, laura
  • turunen, minna
  • karhemo, piia-riitta
  • bergman, paula
  • risteli, maija
  • åström, pirjo
  • tiikkaja, riia
  • grenman, reidar
  • wennerberg, krister
  • monni, outi
  • salo, tuula
Publication Date
Dec 30, 2019
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

In vitro cancer drug testing carries a low predictive value. We developed the human leiomyoma&ndash / derived matrix &ldquo / Myogel&rdquo / to better mimic the human tumor microenvironment (TME). We hypothesized that Myogel could provide an appropriate microenvironment for cancer cells, thereby allowing more in vivo&ndash / relevant drug testing. We screened 19 anticancer compounds, targeting the epidermal growth factor receptor (EGFR), MEK, and PI3K/mTOR on 12 head and neck squamous cell carcinoma (HNSCC) cell lines cultured on plastic, mouse sarcoma&ndash / derived Matrigel (MSDM), and Myogel. We applied a high-throughput drug screening assay under five different culturing conditions: cells in two-dimensional (2D) plastic wells and on top or embedded in Matrigel or Myogel. We then compared the efficacy of the anticancer compounds to the response rates of 19 HNSCC monotherapy clinical trials. Cancer cells on top of Myogel responded less to EGFR and MEK inhibitors compared to cells cultured on plastic or Matrigel. However, we found a similar response to the PI3K/mTOR inhibitors under all culturing conditions. Cells grown on Myogel more closely resembled the response rates reported in EGFR-inhibitor monotherapy clinical trials. Our findings suggest that a human tumor matrix improves the predictability of in vitro anticancer drug testing compared to current 2D and MSDM methods.

Report this publication

Statistics

Seen <100 times